- Conditions
- Influenza
- Interventions
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 424 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Stockbridge, Georgia • Boise, Idaho + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1992
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Sheffield, Alabama • Vestavia Hills, Alabama + 47 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 13
- States / cities
- San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
- Interventions
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Acute Otitis Media (AOM)
- Interventions
- Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Up to 69 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Irritable Mood, Huntington's Disease
- Interventions
- SRX246, Placebo
- Drug
- Lead sponsor
- Azevan Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Primary Myelofibrosis, Myeloproliferative Neoplasm
- Interventions
- Ropeginterferon alfa-2b, Placebo
- Biological · Other
- Lead sponsor
- PharmaEssentia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Kansas City, Kansas + 10 more
- Conditions
- Major Depressive Disorder, Depression
- Interventions
- TC-5214, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
- Conditions
- Endoscopic Retrograde Cholangiopancreatography
- Interventions
- Exalt Model D Single-Use Duodenoscope
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Opioid Use, Pain, Postoperative, Opioid Use, Unspecified, Trauma, Opioid-use Disorder
- Interventions
- Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 783
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Valemetostat tosylate, T-DXd, Dato-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Irvine, California • San Diego, California • Plantation, Florida + 13 more
- Conditions
- Lung Neoplasms, Lung Cancer
- Interventions
- OTL38 for Injection, Near infrared camera imaging system
- Drug · Device
- Lead sponsor
- On Target Laboratories, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Stamford, Connecticut • Iowa City, Iowa • Boston, Massachusetts + 8 more
- Conditions
- AL Amyloidosis
- Interventions
- CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, lenalidomide, bortezomib and dexamethasone
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Up to 70 Years
- Enrollment
- 758 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 54
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 46 more
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Interventions
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Drug
- Lead sponsor
- Hemab ApS
- Industry
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Coronary Artery Disease
- Interventions
- HeartMate PHP, Any Abiomed Impella® device approved for use in high-risk PCI
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 43 more
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Interventions
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more
- Conditions
- HIV Infection
- Interventions
- Highly active antiretroviral therapy (HAART)
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 26
- States / cities
- Alhambra, California • Los Angeles, California • San Diego, California + 20 more
- Conditions
- HIV Infections
- Interventions
- CAB LA, New formulation of CAB LA
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sorafenib Tosylate, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 966
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more
- Conditions
- Dermatitis Atopic
- Interventions
- Lunsekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 23
- States / cities
- Encino, California • Sacramento, California • Thousand Oaks, California + 19 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Alisertib, Placebo, Paclitaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more